MentiNova
Founded
2013
2013
Geography
United States of America based
United States of America based
Funding
$0.500 M
$0.500 M
MentiNova’s primary strategy is to use L-DOPA, the drug that is currently clinically approved for another indication and repurpose it for the treatment of L-Dopa Induced Dyskinesia in patients with Parkinson’s disease.
Technologies
Pharmaceutical and Drug DiscoveryR&D Platform
Pipelines
No pipelines published yet
Products
Services
No services posted yet
